Cargando…

The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention

OBJECTIVE: Soluble urokinase-type plasminogen activator receptor (SuPAR) is a circulating protein and a novel identified promising biomarker for various renal diseases and kidney injury. However, it remains unknown on the predictive value of suPAR in contrast induced acute kidney injury (CI-AKI) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yuhan, Qiao, Yong, Wang, Dong, Yan, Gaoliang, Tang, Chengchun, Ma, Genshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504866/ https://www.ncbi.nlm.nih.gov/pubmed/34675617 http://dx.doi.org/10.2147/IJGM.S339075

Ejemplares similares

The Predictive Value of Myeloperoxidase for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
por: Yan, Gaoliang, et al.
Publicado: (2021)

The Association of Serum Lactate Level with the Occurrence of Contrast-Induced Acute Kidney Injury and Long-Term Prognosis in Patients Undergoing Emergency Percutaneous Coronary Intervention
por: Yan, Gaoliang, et al.
Publicado: (2021)

Association between Serum Ferritin and Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Zhu, Boqian, et al.
Publicado: (2016)

Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome
por: Tang, Chengchun, et al.
Publicado: (2019)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography
por: Sommerer, Claudia, et al.
Publicado: (2019)

Effects of Serum Cytochrome c on Contrast-Induced Nephropathy in Patients with ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
por: Tang, Chengchun, et al.
Publicado: (2019)

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis
por: Li, Yang, et al.
Publicado: (2022)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease
por: Iversen, Esben, et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients
por: Huang, Yuli, et al.
Publicado: (2017)

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans
por: Corban, Michel T., et al.
Publicado: (2018)

Different levels of glycosylated hemoglobin influence severity and long-term prognosis of coronary heart disease patients with stent implantation
por: WANG, JING, et al.
Publicado: (2015)

A High Triglyceride-Glucose Index Is Associated With Contrast-Induced Acute Kidney Injury in Chinese Patients With Type 2 Diabetes Mellitus
por: Qin, Yuhan, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
por: Koh, Angela S., et al.
Publicado: (2017)

Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction
por: Sörensen, Nils A., et al.
Publicado: (2019)

Soluble urokinase-type plasminogen activator receptor in sickle cell disease–associated chronic kidney disease
por: Afangbedji, Nowah, et al.
Publicado: (2022)

Soluble Urokinase‐Type Plasminogen Activator Receptor: A Useful Biomarker for Coronary Artery Disease and Clinical Outcomes?
por: Harskamp, Ralf E., et al.
Publicado: (2014)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders
por: Vasarhelyi, Barna, et al.
Publicado: (2016)

Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis
por: Zhao, Jing-jing, et al.
Publicado: (2018)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
por: Vassiliou, Alice G., et al.
Publicado: (2022)

Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention
por: Wlazeł, Rafał N., et al.
Publicado: (2016)

Glycemic variability as predictor of contrast-induced nephropathy in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention
por: Zuo, Pengfei, et al.
Publicado: (2020)

Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
por: Emrah, Acar, et al.
Publicado: (2016)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity
por: Raff, Hershel, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7o9dj35es59cpj0449qt3tj9pd